Acta Medica Okayama volume75 issue1
2021-02 発行

Treatment Outcomes of Pulmonary Metastases from Head and Neck Squamous Cell Carcinoma

Miyamaru, Satoru Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
Murakami, Daizo Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
Nishimoto, Kohei Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
Saito, Haruki Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
Miyamoto, Yusuke Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
Hirota, Kaoruko Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
Ise, Momoko Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University
Orita, Yorihisa Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University Kaken ID publons researchmap
Publication Date
2021-02
Abstract
Although the lung is the most common site of distant metastases from head and neck squamous cell carcinoma (HNSCC), the number of reports about the effects of pulmonary metastasectomy for the treatment of lung metastasis from HNSCC is limited. Metachronous pulmonary metastases were detected in 45 HNSCC patients at Kumamoto University Hospital from 1998 to 2018. Twenty-two patients underwent an operative resection (Ope group) and 23 underwent chemotherapy (Chemo group). The 3-year overall survival (OS) rate and median OS were evaluated. The effects of adjuvant chemotherapy after pulmonary metastasectomy and of new drugs (cetuximab and nivolumab), in the chemo group were also assessed. The 3-year OS rates and median OS were: Ope, 66.1% and 31.5 months; Chemo, 39.7% and 18 months, respectively. In the Ope group, addi-tional recurrences were significantly fewer in the patients who underwent adjuvant chemotherapy post-surgery versus the patients who underwent surgery alone (p = 0.013). In the Chemo group, the 3-year OS rate of the patients who received new drugs was significantly better than that of the patients who did not (p = 0.021). Adjuvant chemotherapy after pulmonary metastasectomy may be a preferable treatment option for preventing recurrences. Cetuximab and nivolumab have a potential to improve OS.
Document Type
Original Article
Keywords
pulmonary metastasis
head and neck squamous cell carcinoma
pulmonary metastasectomy
adjuvant chemotherapy
Link to PubMed
75_1_31.pdf 2.04 MB